Kathryn Olsen, James Hodson, Vincenzo Ronca, Amber G. Bozward, Jennifer Hayden, Grace Wootton, Matthew Armstrong, David H. Adams, Omar El‐Sherif, James Ferguson, Ellen Knox, Tracey Johnston, Fiona Thompson, Ye Htun Oo – 20 May 2021 – Autoimmune hepatitis (AIH) is an immune‐mediated chronic liver disease that affects all ages, including women of childbearing age. Optimal management during pregnancy is poorly defined.

Kathryn Olsen, James Hodson, Vincenzo Ronca, Amber G. Bozward, Jennifer Hayden, Grace Wootton, Matthew Armstrong, David H. Adams, Omar El‐Sherif, James Ferguson, Ellen Knox, Tracey Johnston, Fiona Thompson, Ye Htun Oo – 20 May 2021 – Autoimmune hepatitis (AIH) is an immune‐mediated chronic liver disease that affects all ages, including women of childbearing age. Optimal management during pregnancy is poorly defined.

Gabriel M. Knight, Jeffrey Clark, Justin R. Boike, Haripriya Maddur, Daniel R. Ganger, Abhinav Talwar, Ahsun Riaz, Kush Desai, Samdeep Mouli, Elias Hohlastos, Juan‐Carlos Garcia Pagan, Ahmed Gabr, Brady Stein, Robert Lewandowski, Bartley Thornburg, Riad Salem – 20 May 2021

Marina Serper, Sunny Y. Tao, Dorothea S. Kent, Patrik Garren, Alexander E. Burdzy, Jennifer C. Lai, Amir Gougol, Pamela M. Bloomer, K. Rajender Reddy, Michael A. Dunn, Andres Duarte‐Rojo – 20 May 2021 – Objective inpatient frailty assessments in decompensated cirrhosis are understudied. We examined the feasibility of inpatient frailty measurements and associations with nonhome discharge, readmission, and all‐cause mortality among patients admitted for cirrhosis complications. We conducted a prospective study at 3 liver transplantation (LT) centers.

Chathur Acharya, Jasmohan S. Bajaj – 20 May 2021 – Cirrhosis is a debilitating chronic disease with high morbidity and mortality, with the only real cure being liver transplantation (LT). Currently, we allocate organs for transplantation based on the Model for End‐Stage Liver Disease–Sodium (MELD‐Na) score that does not account for hepatic encephalopathy (HE). HE affects patients, families, and the health care system because of high rates of recurrence and major readmission burden. Moreover, HE casts a long shadow even after LT.

Kathleen Yan, Lisa Forman – 20 May 2021 – The effect of cannabinoids on liver transplant outcomes is an area of active research. We aimed to investigate marijuana (MJ) and cannabidiol (CBD) use among liver transplant recipients at the University of Colorado Hospital (UCH), specifically prevalence, habits, and predictors of use. Liver transplant recipients followed at UCH with valid email addresses were sent an informed consent postcard and survey invitation. This exploratory survey was conducted using REDCap. IBM SPSS Statistics software was used for statistical analysis.

Mar Miserachs, Penni Kean, Lori Tuira, Yasser Al Nasser, Maria De Angelis, Krista Van Roestel, Anand Ghanekar, Mark Cattral, Marialena Mouzaki, Vicky Lee Ng, Haifa Mtaweh, Yaron Avitzur – 20 May 2021 – Delivery of adequate nutrition after liver transplantation (LT) surgery is an important goal of postoperative care. Existing guidelines recommend early enteral nutrition after abdominal surgery and in the child who is critically ill but data on nutritional interventions after LT in children are sparse.

Habiba Kamal, Omid Sadr‐Azodi, Lars Engstrand, Nele Brusselaers – 20 May 2021

Aurélie Walter, Marika Rudler, Pol Olivas, Lucile Moga, Eric Trépo, Marie Angèle Robic, Isabelle Ollivier‐Hourmand, Anna Baiges, Olivier Sutter, Charlotte Bouzbib, Jean Marie Peron, Vincent Le Pennec, Nathalie Ganne‐Carrié, Juan Carlos Garcia‐Pagán, Maxime Mallet, Hélène Larrue, Thong Dao, Dominique Thabut, Virginia Hernández‐Gea, Jean‐Charles Nault, Christophe Bureau, Manon Allaire, the Salvage TIPS Group – 20 May 2021

Join the Nonalcoholic Fatty Liver Disease Special Interest Group in discussing the current challenges in histological assessment in NASH clinical trials. Presenters will also discuss how to implement hard outcomes in NASH clinical trials and the use non-invasive biomarkers as primary endpoints for drug approval.Naim Alkhouri Naim Alkhouri, MD is the VP of Academic Affairs, Chief of Transplant Hepatology, and Director of the Fatty Liver Program at Arizona Liver Health (ALH) in Phoenix, AZ. Prior to joining ALH, Dr.